Navigation Links
Novagali Pharma Announces the Launch of Cationorm(R)
Date:4/9/2008

The Innovative Cationic Emulsion for the Treatment of Dry Eye Symptoms

An Optimal Solution for Patients

The First Product Developed From its Pipeline to be Marketed

EVRY, France, April 9 /PRNewswire/ -- Novagali Pharma, an ophthalmic specialty pharmaceutical company announces the commercial launch in France of its first product Cationorm(R). This cationic emulsion is an innovative approach to treat dry eye symptoms. It has been developed on the basis of Novagali Pharma patented technology platform Novasorb(R).

Dry eye syndrome is the second cause of consultation in ophthalmology. It concerns over 100 million people in the world and 14% of the adults of more than 40 years. Due to a chronic lack of lubrication and moisture in the eye, its consequences range from irritation to ocular inflammation of the conjunctiva and corneal tissues of the eyes. People with dry eye have sandy-gritty irritation or burning in their eyes. In most severe cases, corneal lesions may lead to vision loss. Specific factors such as ageing populations, pollution, air conditioning, extended use of computers, contribute to an increase in the prevalence of the syndrome and in opportunities for the development of more efficient products.

Cationorm(R) brings a true innovation to the patients suffering from dry eye symptoms. The cationic emulsion reproduces the tear mechanisms of action to act on the different levels of the tear film. Cationorm(R) uniquely combines lubricating and hydrating properties, optimal spreading on the surface of the eye, replenishment of the tear film lipid layer and prevention of tear evaporation. The results of clinical study have clearly demonstrated Cationorm(R) advantages for patients: tolerance, long-lasting relief and optimal comfort.

These advantages are based on Novasorb(R), the proprietary cationic emulsion technology platform of Novagali Pharma. Novasorb(R), is designed to improve topical administ
'/>"/>

SOURCE Novagali Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Ottawa, ON (PRWEB) April 28, 2015 ... CEO and founder, has been selected by the Ottawa ... 40 Under 40. Dr. Lem was selected from over ... and community involvement. , Prior to Spartan, Dr. Lem ... Management at DNA Genotek. He holds a Medical Degree ...
(Date:4/27/2015)... Kan. , April 27, 2015  For ... cancer cells is their ability to utilize and ... alteration of cancer cells is called the ,Warburg ... in spite of high oxygen presence, leading to ... oxygen, cancer cells still choose glucose fermentation. A ...
(Date:4/27/2015)... San Diego, Calif. (PRWEB) April 27, 2015 ... mechanisms of drug and chemical toxicity carries implications for ... featured speaker April 28 at National University , ... reception and presentation by Dr. Hanzlik, a professor at ... in drug metabolism and drug design, starts at 5 ...
(Date:4/27/2015)... , 27 avril 2015 ... spécialisée dans le développement d,une nouvelle ... les infections bactériennes polypharmacorésistantes potentiellement mortelles, ... données prouvant les promesses de son ... la lutte contre la résistance aux ...
Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... (Nasdaq: KNSY ) today announced that it ... SPNC ) that they reached a cumulative $20 million ... from Kensey Nash in May 2008. Accordingly, this triggered ... Nash.  As previously disclosed, the Company expects to record ...
... 2011  Stemline Therapeutics, Inc. today announced that Ivan Bergstein, ... present at the Oppenheimer 22nd Annual Healthcare Conference on ... the Waldorf Astoria Hotel in New York City. ... Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company ...
... Insurance Company, a Medicare Part D provider, with offices ... arbitration between the company and ProCare, its former pharmacy ... suit against ProCare based on Fox,s allegations of negligence ... Barotz, chairman of Fox Insurance Company commented: "Fox Insurance ...
Cached Biology Technology:Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager 2
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... The plant hormone indole-3-acetic acid (IAA), commonly referred to ... growth and development. Auxin influences development by affecting the ... cell division and cell expansion in specific plant tissues ... e.g. for leaves, roots, and floral organs to develop ...
... or Sultans of Soil, they're just clever Lab guys. A ... this week's Science Magazine with a new way to count ... world beneath our feet. , "Computational Improvements Reveal Great Bacterial ... Murray Wolinsky and John Dunbar, of Los Alamos' Bioscience Division, ...
... In 1909, while harvesting a typical corn crop (Zea mays) ... that it was initially believed to be a new species. ... and the specimen was designated Zea ramosa (from the Latin ... single gene, later named ramosa1, both the ear and the ...
Cached Biology News:Scientists find microRNAs regulate plant development 2Scientists find microRNAs regulate plant development 3Scientists find microRNAs regulate plant development 4Comparison of Cocaine, Methamphetamine ‘Highs?Finds Differences 2$6.5 Million Grant for Microarray Center at Yale School of Medicine 2
... Signet Level 2 Detection System combines ... chemical bonding principle and Signets unique ... sensitivity, specificity and reliablility. Signet reagents ... both manual and automated protocols. ,Signets ...
... Signet Level 2 Detection System combines ... chemical bonding principle and Signets unique ... sensitivity, specificity and reliablility. Signet reagents ... both manual and automated protocols. ...
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Biology Products: